Consensus statement on the treatment of transplant-eligible patients with newly diagnosed multiple myeloma in New Zealand.
N Z Med J
; 133(1527): 104-110, 2020 12 18.
Article
em En
| MEDLINE
| ID: mdl-33332332
ABSTRACT
Multiple myeloma is the second most common blood cancer in New Zealand with higher incidence in Maori and Pacific Island populations. It remains an incurable disease but the rapidly changing treatment landscape has led to improved outcome. In response to recent changes in funding of anti-myeloma therapy in New Zealand, the New Zealand Myeloma Interest Group has reviewed the latest literature and updated the treatment pathway of transplant-eligible patients with newly diagnosed multiple myeloma.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Protocolos de Quimioterapia Combinada Antineoplásica
/
Transplante de Medula Óssea
/
Quimioterapia de Consolidação
/
Quimioterapia de Indução
/
Quimioterapia de Manutenção
/
Mieloma Múltiplo
Tipo de estudo:
Diagnostic_studies
/
Guideline
País/Região como assunto:
Oceania
Idioma:
En
Revista:
N Z Med J
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Nova Zelândia